Effect of Ala-2-D-Trp-8-D-Cys-14-somatostatin on the arginine induced release of insulin, GH and glucagon in normal men.
The effects of several doses of somatostatin (SS) and the analog Ala-2-D-Trp-8-D-Cys-14-SS on the arginine-induced release of insulin, glucagon, and GH were compared in a group of normal human subjects. Somatostatin suppressed the release of insulin, glucagon and GH when administered in a dose of 100 micrograms/hr. The same dose of Ala-2-D-Trp-8-D-Cys-14-SS inhibited GH and glucagon release, but although insulin levels were decreased about 24%, this inhibition was not significant statistically. Higher doses of Ala-2-D-Trp-8-D-Cys-14-SS (300 micrograms/hr) induced a partial inhibition of insulin secretion and completely blocked GH release. These results indicate that in humans this analog is a less potent inhibitor of insulin release than somatostatin.
D000328:Adult; D001120:Arginine / Q000494:pharmacology*; D005934:Glucagon / Q000097:blood*; D013006:Growth Hormone / Q000097:blood*; D006801:Humans; D007328:Insulin / Q000097:blood*; D008297:Male; D013004:Somatostatin / Q000031:analogs & derivatives* / Q000494:pharmacology*
D007328:Insulin; D013004:Somatostatin; C026357:somatostatin, Ala(2)-Trp(8)-Cys(14)-; D013006:Growth Hormone; D005934:Glucagon; D001120:Arginine